Metrics to compare | 4598 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4598PeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.0x | −7.2x | −0.4x | |
PEG Ratio | −0.04 | −0.44 | 0.00 | |
Price/Book | −8.2x | 3.0x | 2.6x | |
Price / LTM Sales | - | 33.1x | 3.0x | |
Upside (Analyst Target) | - | 148.7% | 56.5% | |
Fair Value Upside | Unlock | −1.6% | 8.5% | Unlock |
Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase 1/2 clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase II/III clinical trials for the treatment of solid cancer; DFP-11207, which in phase I/II clinical trial to treat pancreatic cancer; DFP-14927 that is in phase I for the treatment of hematologic cancer; and DFP-10825, to treat gastric/ovarian cancer. The company was incorporated in 2010 and is headquartered in Tokushima, Japan.